Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk

Ejemplares similares

• Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
  por: Changhu Sun, et al.
  Publicado: (2025)
• Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
  por: Na Tian, et al.
  Publicado: (2025)
• Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
  por: Takao Miwa, et al.
  Publicado: (2026)
• Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
  por: Pei‐Chien Tsai, et al.
  Publicado: (2025)
• Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
  por: C. C. Mark Cheah, et al.
  Publicado: (2025)